USA: Green Petrochemical Co-Monomers Arcanum, Axens Begin Producing 1-Butene at US Plant
Arcanum Infrastructure is using Axens’ Alpha Butol technology to produce 1-Butene at its Raven 1-Butene plant in Texas, USA. This project is the first startup for Axens on American soil.
Texas/USA – Arcanum Infrastructure and Axens have recently announced the successful ongoing operations and production of 1-Butene at Raven 1-Butene which is an asset based on Axens Alpha Butol technology.
“We are excited to announce the successful operation of the first asset under the Arcanum platform. We are very happy with the support and partnership of Axens as a licensor for the Raven Butene-1 project”, states Ted Pettijohn, President Arcanum Infrastructure, and Raven Butene-1.
Raven Butene-1’s General Manager, Nicholas Stewart added: “We initiated the startup activities late last year and reached full performance around mid-year. Starting a new process during normal times is challenging but Covid-19 made it even more complicated. The whole Raven team including Axens really pulled together well to insure a safe, efficient operation.”
The successful startup and operation of Raven Butene-1 represents yet another example of Axens Alpha Butol flexibility, and ability to produce best in-class sustainable petrochemical co-monomers. Alpha Butol is the highest reliable and cost-effective process for on purpose high purity 1-Butene production used as co-monomers in the production of various types of polyethylene plastic.
“Today marks not only another achievement to the successful track record of Alpha Butol, but also its first startup on American soil. We congratulate the Raven Butene-1 team and Arcanum Infrastructure on this significant milestone and are pleased to renew Axens’ commitment throughout the Raven project life cycle,” said Jean Sentenac, Axens CEO.
Axens’ Alpha Butol is the world leading technology for the production of on-purpose high purity 1-Butene through ethylene dimerisation. It belongs to a family of technologies based on homogenous catalysis for which extensive research and development has been performed since the mid-60’s. Since the process operates in the liquid phase using a soluble catalyst system which avoids isomerisation of 1-Butene into 2-Butene, there is no need for super-fractionation of the product stream.